Business
Mainz Biomed Today to Provide Corporate Update for First Half of 2022
Company to Host Webcast Today - July 12th - at 4.00pm ET BERKELEY, Calif. and MAINZ, Germany, July 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Company to Host Webcast Today - July 12th - at 4.00pm ET\nBERKELEY, Calif. and MAINZ, Germany, July 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, will host a webcast today - July 12, 2022 at 4:00pm ET - to provide an update on the Company’s progress for the first half of 2022, and to outline the plan for the balance of the fiscal year. The webcast will offer the investment community a comprehensive briefing by Mainz’s executive management team on the Company’s flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) which is being commercialized internationally through a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. The presentation will also include an update on the status of ColoAlert’s U.S. regulatory approval pathway, the ongoing R&D efforts to potentially upgrade ColoAlert’s technical profile to achieve “gold standard” status for CRC at-home testing, an overview of additional products in development, and the Company’s go-forward strategy to facilitate growth. “Given the progress achieved over the past six months across all aspects of the company, the management and Board thought it was appropriate to host this interactive forum to provide an overall update on progress, especially in light of our recent transition to the public sector this past November,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We look forward to providing a detailed presentation covering ColoAlert’s commercial execution and clinical development status along with commentary on the balance of the product development pipeline, and our overall strategy to become a leading oncology focused diagnostic company.” Mainz Biomed - Mid-Year UpdateConference ID: 13730909Date and Time: Tuesday July 12, 2022, 4:00 PM ET To access the webcast, please register HERE For dial in access, please use the following:Toll Free: 1-877-269-7751Toll/International: 1-201-389-0908 The Mainz mid-year update will be made available for replay for 14 days after the event. The webcast replay can be accessed HEREToll Free: 1-844-512-2921Toll/International: 1-412-...